Retrospective Study
Copyright ©The Author(s) 2025.
World J Gastroenterol. Mar 14, 2025; 31(10): 102393
Published online Mar 14, 2025. doi: 10.3748/wjg.v31.i10.102393
Table 1 Demographic and clinicopathological data of 32 patients with oesophageal gastrointestinal stromal tumour, n (%)
Parameter
Variable
Age, mean ± SD (year)57.78 ± 7.39
    < 504 (12.5)
    ≥ 5028 (87.5)
Sex
    Male18 (56.3)
    Female14 (43.8)
Localization
    Upper2 (6.3)
    Middle10 (31.3)
    Lower20 (62.5)
Tumour size (cm)2.12 ± 1.88 (median: 1.50, range: 0.80-2.75)
Mitotic rate
    Mean (per 50 HPF, ± SD)3.34 ± 5.04
    Median (per 50 HPF, range)1.50 (1.00-4.00)
NIH risk category
    High6 (18.8)
    Intermediate2 (6.3)
    Low6 (18.8)
    Very Low18 (56.3)
Symptoms
    Asymptomatic (discovered incidentally)28 (87.5)
    Abdominal pain3 (9.4)
    Obstruction1 (3.1)
Operation time, mean (± SD), minute52.63 ± 43.29
Hospital stay duration, mean (± SD), day4.22 ± 2.21
Surgical resection
    En bloc resection31 (96.9)
    ER0 resection32 (100)
    R0 resection24 (75.0)
    R1 resection8 (25.0)
Tumour growth pattern
    Intraluminal growth29 (90.6)
    Extraluminal growth3 (9.4)
Complication8 (25.0)
    Hydrothorax4 (12.5)
    PEECS5 (15.6)
Table 2 Survival data of 32 cases of oesophageal gastrointestinal stromal tumour, n (%)
Parameter
Variable
Treatment
    Imatinib2 (6.3)
    Wait and see30 (93.7)
Follow-up time
    Mean (mean ± SD)64.69 ± 33.13
    Median (month, range)65.50 (37.75-93.00)
Survival data
    Recurrence3
    GISTs-related deaths0
Survival rates (%)
1-/3-/5-year OS100/100/100
1-/3-/5-year DFS100/90.6/90.6
Table 3 Tumour characteristics of recurrence
Patient
Location
Size, cm
Mitotic rates
Growth pattern
Margin status
Classification of tumour
Connection to MP layer
Follow-up time, months
Imatinib time, months
Reoperation
Survive
1Middle71ExtraluminalR1High riskYes33NoNoYes
2Lower20IntraluminalR0Very low riskYes107NoNoYes
3Lower17IntraluminalR0Low riskYes40NoNoYes